Evidence map›Paper›PMID 33084052›Full record

Trial reportJournal of clinical pharmacology2021

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.

Richard A Preston, Thomas Marbury, Ganesh Balaratnam, Michelle Green, Sandy Dixon, Josh Lehrer-Graiwer, Carla Washington

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Richard A PrestonClinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Thomas MarburyOrlando Clinical Research Center, Orlando, Florida, USA.
Ganesh BalaratnamMyoKardia, South San Francisco, California, USA.
Michelle GreenIntegrated Drug Development, Certara, Menlo Park, California, USA.
Sandy DixonGlobal Blood Therapeutics, South San Francisco, California, USA.
Josh Lehrer-GraiwerGlobal Blood Therapeutics, South San Francisco, California, USA.
Carla WashingtonGlobal Blood Therapeutics, South San Francisco, California, USA.
Global Blood Therapeutics (United States) · USCertara (United States) · USFluidigm (United States) · USMiami Transplant Institute · USOrlando Clinical Research Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two open-label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m

Indexed as

AdultAgedArea Under CurveBenzaldehydesBody Mass IndexDose-Response Relationship, DrugFemaleGlomerular Filtration RateHalf-LifeHematologic AgentsHepatic InsufficiencyHumansMaleMiddle AgedPyrazinesPyrazolesBenzaldehydesHematologic AgentsPyrazinesPyrazolesvoxelotorhepatic impairmentpharmacokineticsrenal impairmentsickle cell diseasevoxelotor

Identifiers

PMID33084052
PMCPMC7984382
OpenAlexW3094399064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.